{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056870","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.114726+00:00","generated_at":"2026-06-02T06:40:44.580611+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nkarta Q1 net loss $29.5M; cash $450M; NKX019 lupus dosing on track","bullets":["Cash, equivalents and investments of $450.0M at March 31, 2024, including $240.1M from March offering.","Net loss of $29.5M ($0.58 per share) for Q1 2024; R&D expense $25.2M, G&A $7.5M.","First patient dosing with NKX019 in lupus nephritis expected H1 2024; IND cleared 4Q2023.","Preliminary NKX019 compressed dosing data in NHL expected mid-2024; 4/4 re-treated patients achieved CR.","Cash runway expected to fund operations into late 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056870","json":"https://secwatch.observer/filing/0000950170-24-056870.json","markdown":"https://secwatch.observer/filing/0000950170-24-056870.md","text":"https://secwatch.observer/filing/0000950170-24-056870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024056870/0000950170-24-056870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024056870/nktx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:40:44.580611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bd772e015324e8a6d89307bc5de93bb04512928","claim":"Nkarta, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024., EPS $0.58 per basic and diluted share.","evidence_excerpt":"Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024056870/0000950170-24-056870-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024."},{"label":"EPS","value":"$0.58 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}